期刊文献+

肥胖及脂质代谢紊乱对肝移植术预后的影响

Effect of obesity and lipid metabolism disorders on the prognosis of liver transplantation
在线阅读 下载PDF
导出
摘要 肥胖和脂质代谢紊乱与多种疾病之间存在密切关系,在临床中被认为是影响肝移植术预后的重要因素。肥胖和脂质代谢紊乱均与肝移植术后并发症的发生率和严重程度呈正相关,尤其当肥胖与脂质代谢紊乱同时存在时,对肝移植术预后的不良影响更为显著。因此,在肝移植围手术期,应充分评估患者的肥胖和脂质代谢情况,并采取相应的干预措施。深入研究肥胖、脂质代谢紊乱与肝移植术之间的关系,有助于从新的角度揭示影响肝移植术预后的因素,为改善肝移植术预后及开发新的治疗方法提供理论依据与指导。 Obesity and lipid metabolism disorders are closely related to various diseases and are considered important factors affecting the prognosis of liver transplantation in clinical practice.Both obesity and lipid metabolism disorders are positively correlated with the incidence and severity of post-liver transplant complications,with the adverse effects on prognosis being more significant when these conditions coexist.Therefore,it is crucial to thoroughly assess patient’s obesity and lipid metabolism status during the perioperative period of liver transplantation and implement appropriate interventions.In-depth research into the relationship between obesity,lipid metabolism disorders and liver transplantation can reveal potential factors influencing transplant prognosis from new perspectives,providing theoretical basis and guidance for improving post-transplant outcomes and developing new therapeutic strategies.
作者 赵昱博 马艳波 ZHAO Yubo;MA Yanbo(First Clinical Medical College,Shanxi Medical University,Taiyuan 030001;Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation Center,First Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处 《临床与病理杂志》 CAS 2024年第5期746-751,共6页 Journal of Clinical and Pathological Research
关键词 肥胖 脂质代谢紊乱 肝移植 预后 影响 obesity lipid metabolism disorders liver transplantation prognosis impact
  • 相关文献

参考文献6

二级参考文献46

  • 1Mathers CD,Boerma T,Ma Fat D.Global and regional causes of death[J].Br Med Bull,2009,92:7-32.
  • 2Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment:prospective metaanalysis of data from 90,056 participantsin 14 randomised trials of statins[J].Lancet,2005,366:1267-1278.
  • 3Generaux GT,Bonomo FM,Johnson M,et al.Impact of SLCO1B1(OATP1B1)and ABCG2(BCRP)genetic polymorphisms and inhibition on LDL-Clowering and myopathy of statins[J].Xenobiotica,2011,41:639-651.
  • 4Daly AK.Pharmacogenetics and human genetic polymorphisms[J].Biochem J,2010,429:435-49.
  • 5Tohkin M,Ishiguro A,Kaniwa N,et al.Prediction of severe adversedrug reactions using pharmacogenetic biomarkers[J].Drug MetabPharmacokinet,2010,25:122-33.
  • 6Bai JP.Ongoing challenges in drug interaction safety:from exposure topharmacogenomics[J].Drug Metab Pharmacokinet,2010,25:62-71.
  • 7Schwarz UI,Ritchie MD,Bradford Y,et al.Genetic determinants of response towarfarin during initial anticoagulation[J].N Engl J Med,2008,358:999-1008.
  • 8Mega JL,Close SL,Wiviott SD,et al.Cytochrome P-450 polymorphisms andresponse to clopidogrel[J].N Engl J Med,2009,360:354-362.
  • 9Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response toclopidogrelandcardiovascularevents[J].NEnglJMed,2009,360:363-375.
  • 10Cropp CD,Yee SW,Giacomini KM.Genetic variation in drug transportersin ethnic populations[J].Clin Pharmacol Ther,2008,84:412-416.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部